{"id":"https://openalex.org/W4400108733","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.e20516","title":"Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.","display_name":"Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4400108733","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.e20516"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.e20516","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.e20516","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e20516","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014832426","display_name":"Binay K Kshetree","orcid":"https://orcid.org/0000-0002-9376-8603","observed_orcids":["https://orcid.org/0000-0002-9376-8603"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Binay Kshetree","raw_affiliation_strings":["University of Alabama at Birmingham, Montgomery Regional Medical Campus, Montgomery, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Montgomery Regional Medical Campus, Montgomery, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111241857","display_name":"Supradepti Bhandari","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799448541","display_name":"Chitwan Medical College","ror":"https://ror.org/009fgen45","country_code":"NP","type":"other","lineage":["https://openalex.org/I2799448541"]}],"countries":["NP"],"is_corresponding":false,"raw_author_name":"Supradepti Bhandari","raw_affiliation_strings":["Chitwan Medical College, Chitwan, Nepal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chitwan Medical College, Chitwan, Nepal","institution_ids":["https://openalex.org/I2799448541"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"e20516","last_page":"e20516"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8384000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8384000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0794999971985817,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.05820000171661377,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8899999856948853},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9729999899864197},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.875},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9430000185966492},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.8579999804496765},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.8939999938011169},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9739999771118164},{"id":"https://openalex.org/keywords/pembrolizumab-plus-chemotherapy","display_name":"pembrolizumab plus chemotherapy","score":0.7070000171661377},{"id":"https://openalex.org/keywords/drug-approval-timelines","display_name":"drug approval timelines","score":0.5189999938011169},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7229999899864197},{"id":"https://openalex.org/keywords/racial-disparities-in-survival","display_name":"racial disparities in survival","score":0.6129999756813049},{"id":"https://openalex.org/keywords/seer-database","display_name":"SEER database","score":0.6209999918937683},{"id":"https://openalex.org/keywords/radiotherapy","display_name":"radiotherapy","score":0.5220000147819519}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8986396789550781},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5491431951522827},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.532281756401062},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49406149983406067},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.47048643231391907},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4633086025714874},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.42734119296073914},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4089759588241577},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1850685179233551},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.08394375443458557}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.e20516","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.e20516","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e20516","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0},{"display_name":"Reduced inequalities","id":"https://metadata.un.org/sdg/10","score":0.4074000120162964}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3172134436","https://openalex.org/W2911249025","https://openalex.org/W4412756444","https://openalex.org/W4318070818","https://openalex.org/W7162626462","https://openalex.org/W4403822805","https://openalex.org/W4315865962","https://openalex.org/W3202925640","https://openalex.org/W2947510762","https://openalex.org/W3157516959"],"abstract_inverted_index":{"e20516":[0],"Background:":[1],"Metastatic":[2],"non-small":[3],"cell":[4],"lung":[5],"cancers":[6],"(NSCLC)":[7],"are":[8],"being":[9],"treated":[10],"with":[11,80,126,283,287],"immune":[12],"checkpoint":[13],"inhibitors":[14],"(ICI).":[15],"Nivolumab":[16],"was":[17,92,116,132,142,149,169,184,235],"approved":[18],"in":[19,25,32,42,112,209,253,256,271,277],"2015,":[20],"pembrolizumab":[21],"(pz)":[22],"/atezolizumab":[23],"(az)":[24],"2016,":[26],"pz-chemotherapy":[27],"(Ch)":[28],"(pemetrexed":[29],"+":[30],"carboplatin)":[31],"2017;":[33],"durvalumab,":[34],"pz-Ch":[35],"(paclitaxel)":[36],"and":[37,55,64,105,123,164,200,224,243,266],"az-Ch":[38],"(bevacizumab,":[39],"carboplatin,":[40],"paclitaxel)":[41],"2018.":[43],"We":[44,60],"aim":[45],"to":[46,173,176,212],"study":[47,259,273],"population":[48],"based":[49],"overall":[50],"survival":[51,166,179,251,294],"(OS)":[52],"differences":[53],"before":[54],"after":[56,296],"these":[57,113],"approval.":[58],"Methods:":[59],"used":[61,150],"Surveillance,":[62],"Epidemiology":[63],"End":[65],"Results":[66],"(SEER)":[67],"research":[68],"plus":[69],"database":[70],"(Nov":[71],"2022":[72],"submission,17":[73],"registries).":[74],"Patients":[75],"aged":[76],"\u2265":[77],"20":[78],"years":[79],"NSCLC":[81,160,255],"as":[82,94,208],"\u201cdistant\u201d":[83],"(combined":[84],"summary":[85],"stage)":[86],"from":[87,96,102,108,161,167],"2013-2018":[88],"were":[89,124,220],"included.":[90],"Time":[91],"stratified":[93],"Pre-ICI":[95],"2013-2014,":[97],"initial":[98],"single":[99],"agent":[100],"ICI":[101,199,248],"2015-2016":[103],"(ICI)":[104],"new":[106,284,288],"ICI/ICI-Ch":[107],"2017-2018":[109,168],"(n/ICICh).":[110],"OS":[111],"time":[114],"periods":[115],"calculated":[117],"using":[118,134],"Kaplan":[119],"Meier":[120],"(KM)":[121],"method":[122],"compared":[125,211],"log":[127],"rank":[128,188],"tests.":[129],"Multivariate":[130],"analysis":[131,282],"done":[133],"cox":[135],"proportional":[136],"hazard":[137],"ratios.":[138],"p":[139,193],"<":[140,194],"0.05":[141],"considered":[143],"for":[144,151],"statistical":[145],"significance.":[146],"IBM":[147],"SPSS":[148],"analysis.":[152],"Results:":[153],"Total":[154],"of":[155,206,232],"6375":[156],"patients":[157],"had":[158,202,228],"advanced":[159,254],"2013-2018.":[162],"4":[163],"5-year":[165],"not":[170],"available":[171],"due":[172],"data":[174],"up":[175],"2020.":[177],"The":[178],"difference":[180,238],"among":[181,239,244],"three":[182],"timelines":[183,289],"statistically":[185],"significant":[186,237],"(log":[187],"test,":[189],"\u03c72":[190],"=":[191],"20.795,":[192],"0.001).":[195],"On":[196],"multivariate":[197],"analysis,":[198],"n/ICICh":[201],"significantly":[203],"lower":[204,230],"risk":[205,223,231],"dying":[207],"table":[210],"Pre-ICI.":[213],"Male,":[214],"age":[215,268],"\u226550":[216],"years,":[217],"Black/Asian/Pacific":[218],"Islanders":[219],"at":[221],"higher":[222],"who":[225],"received":[226],"radiotherapy/chemotherapy":[227],"a":[229],"dying.":[233],"There":[234],"no":[236],"Hispanic":[240],"versus":[241],"non-Hispanic":[242],"marital":[245],"status.":[246],"Conclusions:":[247],"shows":[249],"clear":[250],"benefits":[252,295],"this":[257,272],"population-based":[258,293],"which":[260],"supports":[261],"clinical":[262],"trials.":[263],"Racial,":[264],"gender":[265],"older":[267],"disparities":[269],"shown":[270],"will":[274,290],"further":[275],"help":[276,291],"guiding":[278],"appropriate":[279],"measures.":[280],"Future":[281],"ICI/Ch":[285],"therapy":[286],"show":[292],"updated":[297],"database.":[298],"[Table:":[299],"see":[300],"text]":[301]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2024-06-29T00:00:00"}